|

A Three-part First-in-human Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GUB-UCN2 in Healthy Lean and Obese Participants and Participants With T2D

RECRUITINGPhase 1/2Sponsored by Gubra A/S
Actively Recruiting
PhasePhase 1/2
SponsorGubra A/S
Started2026-07
Est. completion2028-12
Eligibility
Age18 Years – 75 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07702890

Summary

The trial will enroll healthy volunteers and individuals living with obesity, with and without Type 2 Diabetes. The study, with a treatment period of up to 16 weeks in selected cohorts, will investigate GUB-UCN2 as both a standalone therapy and on top of standard of care for obesity

Eligibility

Age: 18 Years – 75 YearsHealthy volunteers accepted
Inclusion Criteria:

Part 1

* Signed and dated informed consent obtained before any trial-related activities
* Males and female participants, aged between 18-55 years
* Body Mass Index (BMI) between 20.0 and 29.9 kg/m\^2, inclusive
* Considered generally healthy upon completion of medical history and screening safety assessments

Part 2

* Signed and dated informed consent obtained before any trial-related activities
* Male participants, aged between 18-55 years
* Body Mass Index (BMI) between 30.0 and 35.0 kg/m\^2, inclusive

Part 3 (participants with obesity)

* Signed and dated informed consent obtained before any trial-related activities
* Males and female participants, aged between 18-75 years
* Body Mass Index (BMI) between 30.0 and 45.0 kg/m\^2

Part 3 (participants with T2D)

* Signed and dated informed consent obtained before any trial-related activities
* Male and female participants, aged between 18-75 years
* Body Mass Index (BMI) between 27.0 and 35.0 kg/m\^2
* Diagnosed with type 2 diabetes mellitus, HbA1c ≤ 69.0 mmol/mol (≤ 8.5%)
* Stable daily dose of antidiabetic medication

Exclusion Criteria:

* Known history of serious adverse reactions or serious hypersensitivity to drug or formulation excipients
* Presence or history of clinically significant gastrointestinal, cardiovascular, renal, hepatic, dermatological, respiratory, neurological, psychiatric, malignant, metabolic, endocrinological, hematologic or venereal disorder
* Use or planned use of concomitant medication impacting the assessment of trial endpoints
* Clinically significant abnormal laboratory parameters
* Women of childbearing potential who are not using highly effective contraception

Conditions3

DiabetesObesityType 2 Diabetes

Interventions1

GUB-UCN2

Browse More Trials

Diabetes trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.